We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Share Name | Share Symbol | Market | Type |
---|---|---|---|
Pharmaceutical Prod Dev (MM) | NASDAQ:PPDI | NASDAQ | Common Stock |
Price Change | % Change | Share Price | Bid Price | Offer Price | High Price | Low Price | Open Price | Shares Traded | Last Trade | |
---|---|---|---|---|---|---|---|---|---|---|
0.00 | 0.00% | 33.24 | 0 | 01:00:00 |
Pharmaceutical drug research company Pharmaceutical Product Development, Inc. (PPDI) recently announced that its shareholders have approved the merger with privately held firms The Carlyle Group and Hellman & Friedman. The merger was announced in October 2011.
PPD shareholders have been offered a cash consideration of $33.25 per share. The total purchase consideration comes to $3.9 billion in cash. The merger is now subject to certain closing conditions and is expected to close before the end of 2011, following which PPD will become a private company and will no longer trade on NASDAQ.
Four banks have committed to finance the deal. These include Credit Suisse (CS), JP Morgan (JPM), Goldman Sachs (GS) and UBS (UBS). Because of the buyout, PPD did not hold a conference call to discuss the third quarter results.
Our Recommendation
We currently have a Hold recommendation on PPD. The company retains a Zacks #3 Rank, which translates into a short-term Hold rating. We are impressed by the company’s strong bookings, stable backlog duration and sound expense control.
PPD is a leading contract research organization (CRO) providing drug discovery and development services to pharmaceutical and biotechnology companies. Companies like PPD and Charles River Laboratories (CRL) suffered in 2008-2009 due to a decline in demand for their services in time of a depressed economy.
The environment for CROs is gradually improving. Higher request for proposals (RFP) flows and key strategic partnerships secured by PPD with bio-pharma customers are a testament to such a revival, which would in turn result in bottom-line growth. However, we remain concerned about the high cancellation rates.
1 Year Pharmaceutical Product Developme Chart |
1 Month Pharmaceutical Product Developme Chart |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions